US Renal Denervation Devices Market
Description
US Renal Denervation Devices Market Overview
The US Renal Denervation Devices Market is valued at USD 440 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of hypertension and the rising demand for minimally invasive procedures, with a large hypertensive population and high cardiovascular burden in the United States supporting adoption. The market is also supported by advancements in technology, including next?generation catheters and energy delivery systems, which enhance the efficacy and safety of renal denervation procedures and make them more appealing to both healthcare providers and patients. The United States dominates the renal denervation devices market within North America due to its advanced healthcare infrastructure, high healthcare expenditure, and the strong presence of leading medical device companies. A significant number of clinical trials and research activities in major academic and cardiovascular centers underpin early adoption of renal denervation technologies and continuous evidence generation for treatment of uncontrolled hypertension. In 2023, the US Food and Drug Administration approved dedicated renal denervation systems for the treatment of hypertension, including Medtronic’s radiofrequency?based Symplicity Spyral Renal Denervation System and ReCor Medical’s ultrasound?based Paradise Ultrasound Renal Denervation System, under the premarket approval pathway. These approvals are supported by requirements for robust clinical evidence on blood pressure reduction and safety, including post?approval study commitments, and they have expanded patient access to innovative catheter?based hypertension treatments while maintaining stringent device safety and performance standards.
US Renal Denervation Devices Market Segmentation
By Device Type: The renal denervation devices market is segmented into various device types, including Radiofrequency (RF) Renal Denervation Systems, Ultrasound-based Renal Denervation Systems, Chemical/Neurolytic Denervation Systems, and Pulsed-field/Electroporation and Other Emerging Modalities. This structure is consistent with how leading market studies classify technologies by energy source. Among these, Radiofrequency (RF) systems are currently leading the market due to their established efficacy, extensive clinical trial data, and widespread acceptance in clinical practice. The RF systems are favored for their ability to deliver precise energy to the renal nerves via multi?electrode catheters, supporting durable reductions in blood pressure in patients with uncontrolled hypertension. By Procedure Approach: The market is also segmented by procedure approach, which includes Percutaneous Catheter-based Renal Denervation, Combination/Adjunctive Renal Denervation Procedures, and Other Clinical Techniques. The Percutaneous Catheter-based approach is the most prevalent due to its minimally invasive nature, catheter-based access via the femoral or radial artery, and the ability to perform the procedure in a catheterization lab setting with short recovery times, which appeals to both patients and healthcare providers. This method has shown promising results in clinical studies of patients with resistant or uncontrolled hypertension, with sustained reductions in office and ambulatory blood pressure, further solidifying its position as the preferred choice.
US Renal Denervation Devices Market Competitive Landscape
The US Renal Denervation Devices Market is characterized by a dynamic mix of regional and international players. Leading participants such as Medtronic plc, Boston Scientific Corporation, ReCor Medical, Inc. (Otsuka Medical Devices), Abbott Laboratories (including legacy St. Jude Medical technology), Terumo Corporation, Ablative Solutions, Inc., Cardiosonic Ltd., MicroPort Scientific Corporation, Nuvectra Corporation, Biotronik SE & Co. KG, AngioDynamics, Inc., Cook Medical LLC, SentreHEART, Inc., Cardiovascular Systems, Inc., and other emerging US renal denervation technology developers contribute to innovation, geographic expansion, and service delivery in this space.
Medtronic plc
1949 Dublin, Ireland
Boston Scientific Corporation
1979 Marlborough, Massachusetts, USA
ReCor Medical, Inc. (Otsuka Medical Devices) 2009 Palo Alto, California, USA
Abbott Laboratories
1888 Abbott Park, Illinois, USA
Terumo Corporation
1921 Tokyo, Japan
Company
Establishment Year
Headquarters
Renal Denervation Devices Revenue (US$, latest year)
US Renal Denervation Market Share (%)
3–5 Year Revenue CAGR in Renal Denervation Segment
Installed Base of Systems in the US (number of centers)
Number of RDN Procedures Supported Annually in the US
Product & Technology Breadth (RF, Ultrasound, Chemical, Pulsed-field)
US Renal Denervation Devices Market Industry Analysis
Growth Drivers
Increasing Prevalence of Hypertension: The prevalence of hypertension in the United States is projected to reach approximately 122 million individuals in future, according to the American Heart Association. This rising number is driven by factors such as an aging population and lifestyle changes, which increase the demand for effective hypertension management solutions. As renal denervation devices offer a novel approach to treating resistant hypertension, their adoption is expected to grow significantly in response to this increasing patient population. Advancements in Renal Denervation Technology: Recent technological advancements have led to the development of more effective renal denervation devices, enhancing their efficacy and safety profiles. For instance, the introduction of multi-electrode systems has improved treatment outcomes, with studies indicating a reduction in systolic blood pressure by an average of 8–10 mmHg. These innovations are crucial in attracting healthcare providers and patients, thereby driving market growth as they seek better hypertension management options. Supportive Reimbursement Policies: The Centers for Medicare & Medicaid Services (CMS) has begun to recognize renal denervation as a viable treatment option, leading to improved reimbursement policies. In future, it is estimated that reimbursement rates for renal denervation procedures will increase by 15%, making these devices more accessible to patients. This financial support encourages healthcare providers to adopt renal denervation technologies, further propelling market growth as more patients receive treatment for hypertension.
Market Challenges
High Cost of Devices: The average cost of renal denervation devices can exceed $20,000, which poses a significant barrier to widespread adoption. Many healthcare facilities face budget constraints, limiting their ability to invest in these advanced technologies. As a result, the high upfront costs can deter healthcare providers from offering renal denervation as a treatment option, impacting overall market growth and patient access to these innovative solutions. Limited Clinical Evidence for Long-Term Efficacy: Despite promising initial results, there remains a lack of extensive clinical data supporting the long-term efficacy of renal denervation devices. Studies have shown mixed results regarding sustained blood pressure reduction beyond 12 months, which raises concerns among healthcare providers. This uncertainty can hinder the adoption of these devices, as clinicians may prefer established treatments with proven long-term outcomes for managing hypertension.
US Renal Denervation Devices Market Future Outlook
The future of the US renal denervation devices market appears promising, driven by ongoing technological advancements and increasing awareness of hypertension management. As healthcare providers continue to embrace minimally invasive procedures, the demand for renal denervation devices is expected to rise. Additionally, the integration of digital health technologies will enhance patient monitoring and treatment adherence, further supporting market growth. The focus on personalized medicine will also play a crucial role in tailoring treatments to individual patient needs, fostering innovation in this sector.
Market Opportunities
Expansion into Emerging Markets: There is significant potential for renal denervation devices in emerging markets, where hypertension rates are rising rapidly. Countries like India and Brazil are experiencing increased healthcare investments, which can facilitate the introduction of these devices. By targeting these regions, companies can tap into a growing patient base seeking effective hypertension treatments, thereby expanding their market presence. Development of Next-Generation Devices: The ongoing research and development of next-generation renal denervation devices present a substantial opportunity for market players. Innovations such as improved catheter designs and enhanced energy delivery systems can lead to better patient outcomes. By investing in R&D, companies can differentiate their products and capture a larger share of the market, meeting the evolving needs of healthcare providers and patients alike.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
The US Renal Denervation Devices Market is valued at USD 440 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of hypertension and the rising demand for minimally invasive procedures, with a large hypertensive population and high cardiovascular burden in the United States supporting adoption. The market is also supported by advancements in technology, including next?generation catheters and energy delivery systems, which enhance the efficacy and safety of renal denervation procedures and make them more appealing to both healthcare providers and patients. The United States dominates the renal denervation devices market within North America due to its advanced healthcare infrastructure, high healthcare expenditure, and the strong presence of leading medical device companies. A significant number of clinical trials and research activities in major academic and cardiovascular centers underpin early adoption of renal denervation technologies and continuous evidence generation for treatment of uncontrolled hypertension. In 2023, the US Food and Drug Administration approved dedicated renal denervation systems for the treatment of hypertension, including Medtronic’s radiofrequency?based Symplicity Spyral Renal Denervation System and ReCor Medical’s ultrasound?based Paradise Ultrasound Renal Denervation System, under the premarket approval pathway. These approvals are supported by requirements for robust clinical evidence on blood pressure reduction and safety, including post?approval study commitments, and they have expanded patient access to innovative catheter?based hypertension treatments while maintaining stringent device safety and performance standards.
US Renal Denervation Devices Market Segmentation
By Device Type: The renal denervation devices market is segmented into various device types, including Radiofrequency (RF) Renal Denervation Systems, Ultrasound-based Renal Denervation Systems, Chemical/Neurolytic Denervation Systems, and Pulsed-field/Electroporation and Other Emerging Modalities. This structure is consistent with how leading market studies classify technologies by energy source. Among these, Radiofrequency (RF) systems are currently leading the market due to their established efficacy, extensive clinical trial data, and widespread acceptance in clinical practice. The RF systems are favored for their ability to deliver precise energy to the renal nerves via multi?electrode catheters, supporting durable reductions in blood pressure in patients with uncontrolled hypertension. By Procedure Approach: The market is also segmented by procedure approach, which includes Percutaneous Catheter-based Renal Denervation, Combination/Adjunctive Renal Denervation Procedures, and Other Clinical Techniques. The Percutaneous Catheter-based approach is the most prevalent due to its minimally invasive nature, catheter-based access via the femoral or radial artery, and the ability to perform the procedure in a catheterization lab setting with short recovery times, which appeals to both patients and healthcare providers. This method has shown promising results in clinical studies of patients with resistant or uncontrolled hypertension, with sustained reductions in office and ambulatory blood pressure, further solidifying its position as the preferred choice.
US Renal Denervation Devices Market Competitive Landscape
The US Renal Denervation Devices Market is characterized by a dynamic mix of regional and international players. Leading participants such as Medtronic plc, Boston Scientific Corporation, ReCor Medical, Inc. (Otsuka Medical Devices), Abbott Laboratories (including legacy St. Jude Medical technology), Terumo Corporation, Ablative Solutions, Inc., Cardiosonic Ltd., MicroPort Scientific Corporation, Nuvectra Corporation, Biotronik SE & Co. KG, AngioDynamics, Inc., Cook Medical LLC, SentreHEART, Inc., Cardiovascular Systems, Inc., and other emerging US renal denervation technology developers contribute to innovation, geographic expansion, and service delivery in this space.
Medtronic plc
1949 Dublin, Ireland
Boston Scientific Corporation
1979 Marlborough, Massachusetts, USA
ReCor Medical, Inc. (Otsuka Medical Devices) 2009 Palo Alto, California, USA
Abbott Laboratories
1888 Abbott Park, Illinois, USA
Terumo Corporation
1921 Tokyo, Japan
Company
Establishment Year
Headquarters
Renal Denervation Devices Revenue (US$, latest year)
US Renal Denervation Market Share (%)
3–5 Year Revenue CAGR in Renal Denervation Segment
Installed Base of Systems in the US (number of centers)
Number of RDN Procedures Supported Annually in the US
Product & Technology Breadth (RF, Ultrasound, Chemical, Pulsed-field)
US Renal Denervation Devices Market Industry Analysis
Growth Drivers
Increasing Prevalence of Hypertension: The prevalence of hypertension in the United States is projected to reach approximately 122 million individuals in future, according to the American Heart Association. This rising number is driven by factors such as an aging population and lifestyle changes, which increase the demand for effective hypertension management solutions. As renal denervation devices offer a novel approach to treating resistant hypertension, their adoption is expected to grow significantly in response to this increasing patient population. Advancements in Renal Denervation Technology: Recent technological advancements have led to the development of more effective renal denervation devices, enhancing their efficacy and safety profiles. For instance, the introduction of multi-electrode systems has improved treatment outcomes, with studies indicating a reduction in systolic blood pressure by an average of 8–10 mmHg. These innovations are crucial in attracting healthcare providers and patients, thereby driving market growth as they seek better hypertension management options. Supportive Reimbursement Policies: The Centers for Medicare & Medicaid Services (CMS) has begun to recognize renal denervation as a viable treatment option, leading to improved reimbursement policies. In future, it is estimated that reimbursement rates for renal denervation procedures will increase by 15%, making these devices more accessible to patients. This financial support encourages healthcare providers to adopt renal denervation technologies, further propelling market growth as more patients receive treatment for hypertension.
Market Challenges
High Cost of Devices: The average cost of renal denervation devices can exceed $20,000, which poses a significant barrier to widespread adoption. Many healthcare facilities face budget constraints, limiting their ability to invest in these advanced technologies. As a result, the high upfront costs can deter healthcare providers from offering renal denervation as a treatment option, impacting overall market growth and patient access to these innovative solutions. Limited Clinical Evidence for Long-Term Efficacy: Despite promising initial results, there remains a lack of extensive clinical data supporting the long-term efficacy of renal denervation devices. Studies have shown mixed results regarding sustained blood pressure reduction beyond 12 months, which raises concerns among healthcare providers. This uncertainty can hinder the adoption of these devices, as clinicians may prefer established treatments with proven long-term outcomes for managing hypertension.
US Renal Denervation Devices Market Future Outlook
The future of the US renal denervation devices market appears promising, driven by ongoing technological advancements and increasing awareness of hypertension management. As healthcare providers continue to embrace minimally invasive procedures, the demand for renal denervation devices is expected to rise. Additionally, the integration of digital health technologies will enhance patient monitoring and treatment adherence, further supporting market growth. The focus on personalized medicine will also play a crucial role in tailoring treatments to individual patient needs, fostering innovation in this sector.
Market Opportunities
Expansion into Emerging Markets: There is significant potential for renal denervation devices in emerging markets, where hypertension rates are rising rapidly. Countries like India and Brazil are experiencing increased healthcare investments, which can facilitate the introduction of these devices. By targeting these regions, companies can tap into a growing patient base seeking effective hypertension treatments, thereby expanding their market presence. Development of Next-Generation Devices: The ongoing research and development of next-generation renal denervation devices present a substantial opportunity for market players. Innovations such as improved catheter designs and enhanced energy delivery systems can lead to better patient outcomes. By investing in R&D, companies can differentiate their products and capture a larger share of the market, meeting the evolving needs of healthcare providers and patients alike.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Table of Contents
97 Pages
- 1. US Renal Denervation Devices Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. US Renal Denervation Devices Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. US Renal Denervation Devices Market Analysis
- 3.1. Growth Drivers
- 3.1.1 Increasing prevalence of hypertension
- 3.1.2 Advancements in renal denervation technology
- 3.1.3 Rising awareness of renal denervation benefits
- 3.1.4 Supportive reimbursement policies
- 3.2. Restraints
- 3.2.1 High cost of renal denervation devices
- 3.2.2 Limited clinical evidence for long-term efficacy
- 3.2.3 Regulatory hurdles and approval delays
- 3.2.4 Competition from alternative hypertension treatments
- 3.3. Opportunities
- 3.3.1 Expansion into emerging markets
- 3.3.2 Development of next-generation devices
- 3.3.3 Collaborations with healthcare providers
- 3.3.4 Increasing investment in renal disease research
- 3.4. Trends
- 3.4.1 Shift towards minimally invasive procedures
- 3.4.2 Integration of digital health technologies
- 3.4.3 Growing patient-centric approaches in treatment
- 3.4.4 Focus on personalized medicine in hypertension management
- 3.5. Government Regulation
- 3.5.1 FDA guidelines for renal denervation devices
- 3.5.2 Compliance with medical device safety standards
- 3.5.3 Regulations on clinical trial protocols
- 3.5.4 Post-market surveillance requirements
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. US Renal Denervation Devices Market Segmentation, 2024
- 4.1. By Device Type (in Value %)
- 4.1.1 Radiofrequency ablation devices
- 4.1.2 Ultrasound-based devices
- 4.1.3 Cryoablation devices
- 4.1.4 Others
- 4.2. By Procedure Type (in Value %)
- 4.2.1 Outpatient procedures
- 4.2.2 Inpatient procedures
- 4.2.3 Hybrid procedures
- 4.3. By End-User (in Value %)
- 4.3.1 Hospitals
- 4.3.2 Specialty clinics
- 4.3.3 Ambulatory surgical centers
- 4.4. By Price Tier (in Value %)
- 4.4.1 Premium devices
- 4.4.2 Mid-range devices
- 4.4.3 Economy devices
- 4.5. By Region (in Value %)
- 4.5.1 Northeast
- 4.5.2 Midwest
- 4.5.3 South
- 4.5.4 West
- 4.5.5 Others
- 4.6. By Patient Demographics (in Value %)
- 4.6.1 Age group
- 4.6.2 Gender
- 4.6.3 Comorbidities
- 5. US Renal Denervation Devices Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1 Medtronic
- 5.1.2 Abbott Laboratories
- 5.1.3 Boston Scientific
- 5.1.4 Johnson & Johnson
- 5.1.5 ReCor Medical
- 5.2. Cross Comparison Parameters
- 5.2.1 No. of Employees
- 5.2.2 Headquarters
- 5.2.3 Inception Year
- 5.2.4 Revenue
- 5.2.5 Production Capacity
- 6. US Renal Denervation Devices Market Regulatory Framework
- 6.1. Medical Device Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. US Renal Denervation Devices Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. US Renal Denervation Devices Market Future Segmentation, 2030
- 8.1. By Device Type (in Value %)
- 8.2. By Procedure Type (in Value %)
- 8.3. By End-User (in Value %)
- 8.4. By Price Tier (in Value %)
- 8.5. By Patient Demographics (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
